Variable absorption of carbidopa affects both peripheral and central levodopa metabolism

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Parkinson disease (PD) is treated with levodopa (LD) and carbidopa (CD).
• CD inhibits peripheral LD decarboxylation, but its absorption variability's effect on LD metabolism is unclear.
• Understanding CD absorption is crucial for optimizing LD therapy in PD.

Purpose of the Study:

• To investigate how variable carbidopa absorption affects peripheral and central levodopa metabolism in Parkinson disease patients.
• To determine if carbidopa doses used in practice saturate peripheral aromatic l-amino acid decarboxylase.
• To correlate carbidopa levels with levodopa's central conversion to dopamine.

Main Methods:

• Stable isotope-labeled levodopa was administered intravenously to 9 PD patients after oral carbidopa.
• Blood and cerebrospinal fluid (CSF) samples were analyzed using HPLC and mass spectrometry.
• Patients were grouped into 'slow' and 'rapid' carbidopa absorbers based on serum levels.

Main Results:

• Poor carbidopa absorbers showed significantly higher peripheral levodopa decarboxylation (p=0.05).
• Rapid carbidopa absorbers had significantly more labeled HVA in CSF, indicating greater central dopamine production (p=0.02).
• A strong correlation was found between serum carbidopa levels and central levodopa conversion (R=0.786, p=0.02).

Conclusions:

• Peripheral aromatic l-amino acid decarboxylase activity may not be saturated at current carbidopa doses.
• Carbidopa absorption significantly influences levodopa's peripheral metabolism and central availability.
• Optimizing carbidopa absorption could enhance levodopa's efficacy in Parkinson disease treatment.